Oruka Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview

Oruka Therapeutics

28/07/2025 12:43

Oruka Therapeutics Inc ORKA.OQ ORKA.O is expected to  report resultson July 30 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Oruka Therapeutics Inc is for a loss of 49 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Oruka Therapeutics Inc is $42.50, about 66.5% above its last closing price of $14.25

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.49
-0.51
-0.40
Beat
20.9
Dec. 31 2025
-0.70
-0.68
-0.49
Beat
28.1
Sep. 30 2024
-0.53
-0.40
-1.46
Missed
-263.3​
​​
​

This summary was machine generated July 28 at 11:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)